|
1
|
Mavrogenis AF, Igoumenou VG,
Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ and Soucacos
PN: Giant cell tumor of bone revisited. SICOT J. 3:542017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H
and Liu W: Giant cell tumor of the extremity: Retrospective
analysis of 621 Chinese patients from one institution. J Bone Joint
Surg Am. 94:461–467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lüke J, Hasenfratz M, Möller P and Barth
TFE: New aspects on giant cell tumor of bone. Pathologe.
39:125–131. 2018.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou Z, Li Y, Xu L, Wang X, Chen S, Yang C
and Xiao J: Biological characteristics of a novel giant cell tumor
cell line derived from spine. Tumour Biol. 37:9681–9689. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fan L, Yin S, Zhang E and Hu H: Role of
p62 in the regulation of cell death induction. Apoptosis.
23:187–193. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sánchez-Martín P, Saito T and Komatsu M:
p62/SQSTM1: ‘Jack of all trades’ in health and cancer. FEBS J.
286:8–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu Y, Wang Q, Zhou Y, Sun L, Hu B, Xue H,
Li M, Zhang K, Ren C, Duan N, et al: Overexpression of p62 is
associated with poor prognosis and aggressive phenotypes in
osteosarcoma. Oncol Lett. 15:9889–9895. 2018.PubMed/NCBI
|
|
8
|
Sha Z, Schnell HM, Ruoff K and Goldberg A:
Rapid induction of p62 and GABARAPL1 upon proteasome inhibition
promotes survival before autophagy activation. J Cell Biol.
217:1757–1776. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Yang Z and Dong J: P62: An
emerging oncotarget for osteolytic metastasis. J Bone Oncol.
5:30–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shaw B, Burrel CL, Green D,
Navarro-Martinez A, Scott D, Daroszewska A, van't Hof R, Smith L,
Hargrave F, Mistry S, et al: Molecular insights into an ancient
form of Paget's disease of bone. Proc Natl Acad Sci USA.
116:10463–10472. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Langer R, Neppl C, Keller MD, Schmid R,
Tschan MP and Berezowska S: Expression analysis of autophagy
related indicators LC3B, p62 and HMGB1 indicate an
autophagy-independent negative prognostic impact of high p62
expression in pulmonary squamous cell carcinomas. Cancers (Basel).
10:2812018. View Article : Google Scholar
|
|
13
|
Karras P, Riveiro-Falkenbach E, Cañón E,
Tejedo C, Calvo TG, Martínez-Herranz R, Alonso-Curbelo D, Cifdaloz
M, Perez-Guijarro E, Gómez-López G, et al: p62/SQSTM1 fuels
melanoma progression by opposing mRNA decay of a selective set of
pro-metastatic factors. Cancer Cell. 35:46–63 e10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xing M, Li P, Wang X, Li J, Shi J, Qin J,
Zhang X, Ma Y, Francia G and Zhang JY: Overexpression of p62/IMP2
can promote cell migration in hepatocellular carcinoma via
activation of the Wnt/β-catenin pathway. Cancers (Basel). 12:72019.
View Article : Google Scholar
|
|
15
|
Umemura A, He F, Taniguchi K, Nakagawa H,
Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S,
Duran A, et al: p62, upregulated during preneoplasia, induces
hepatocellular carcinogenesis by maintaining survival of stressed
HCC-Initiating cells. Cancer Cell. 29:935–948. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moscat J, Karin M and Diaz-Meco MT: p62 in
Cancer: Signaling adaptor beyond autophagy. Cell. 167:606–609.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ponomarenko DM, Klimova ID, Chapygina YA,
Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV,
Burhanova LA, Badrtdinova II, et al: Safety and efficacy of P62 DNA
vaccine ELENAGEN in a first-in-human trial in patients with
advanced solid tumors. Oncotarget. 8:53730–53739. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singer FR: Paget's disease of bone-genetic
and environmental factors. Nat Rev Endocrinol. 11:662–671. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cowan RW and Singh G: Giant cell tumor of
bone: A basic science perspective. Bone. 52:238–246. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lipplaa A, Dijkstra S and Gelderblom H:
Challenges of denosumab in giant cell tumor of bone, and other
giant cell-rich tumors of bone. Curr Opin Oncol. 31:329–335. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Branstetter DG, Nelson SD, Manive JC, Blay
JY, Chawla S, Thomas DM, Jun S and Jacobs I: Denosumab induces
tumor reduction and bone formation in patients with giant-cell
tumor of bone. Clin Cancer Res. 18:4415–4424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chawla S, Henshaw R, Seeger L, Choy E,
Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, et
al: Safety and efficacy of denosumab for adults and skeletally
mature adolescents with giant cell tumor of bone: Interim analysis
of an open-label, parallel-group, phase 2 study. Lancet Oncol.
14:901–908. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mukaihara K, Suehara K, Kohsaka S, Akaike
K, Tanabe T, Kubota D, Ishii M, Fujimura T, Kazuno S, Okubo T, et
al: Protein expression profiling of giant cell tumors of bone
treated with denosumab. PLoS One. 11:e01484012016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lau CP, Huang L, Wong KC and Kumta SM:
Comparison of the anti-tumor effects of denosumab and zoledronic
acid on the neoplastic stromal cells of giant cell tumor of bone.
Connect Tissue Res. 54:439–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
